A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors.

Morita, Sachi; Minami, Hironobu; Mitsuma, Ayako; Toyoda, Masanori; Kiyota, Naomi; Ando, Yuichi

Morita, Sachi; Minami, Hironobu; Mitsuma, Ayako; Toyoda, Masanori; Kiyota, Naomi; Ando, Yuichi.

Afiliação

Morita S; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Minami H; Division of Medical Oncology/Hematology, Department of Internal Medicine, Kobe University Hospital & Graduate School of Medicine, Kobe, Japan.
Mitsuma A; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Toyoda M; Division of Medical Oncology/Hematology, Department of Internal Medicine, Kobe University Hospital & Graduate School of Medicine, Kobe, Japan.
Kiyota N; Division of Medical Oncology/Hematology, Department of Internal Medicine, Kobe University Hospital & Graduate School of Medicine, Kobe, Japan.
Ando Y; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

Asia Pac J Clin Oncol ; 18(5): e427-e434, 2022 Oct.

Article em En | MEDLINE | ID: mdl-35098674

Assuntos

Proteínas Inibidoras de Apoptose; Neoplasias; Teorema de Bayes; Humanos; Proteínas Inibidoras de Apoptose/administração & dosagem; Proteínas Inibidoras de Apoptose/antagonistas & inibidores; Japão; Neoplasias/tratamento farmacológico; Neoplasias/patologia; Paclitaxel; Tiazóis; Resultado do Tratamento

Palavras-chave

Japanese; LCL161; Phase I; paclitaxel; solid tumor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Inibidoras de Apoptose / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google